Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Accumulated Expenses (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Other Accumulated Expenses for 8 consecutive years, with $204000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses fell 48.87% year-over-year to $204000.0, compared with a TTM value of $204000.0 through Sep 2025, down 48.87%, and an annual FY2024 reading of $297000.0, up 15.56% over the prior year.
  • Other Accumulated Expenses was $204000.0 for Q3 2025 at Bicycle Therapeutics, down from $236000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.5 million in Q4 2022 and bottomed at $64000.0 in Q2 2021.
  • Average Other Accumulated Expenses over 5 years is $472789.5, with a median of $309000.0 recorded in 2025.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 1396.88% in 2022, then plummeted 82.54% in 2023.
  • Year by year, Other Accumulated Expenses stood at $570000.0 in 2021, then surged by 158.25% to $1.5 million in 2022, then crashed by 82.54% to $257000.0 in 2023, then increased by 15.56% to $297000.0 in 2024, then plummeted by 31.31% to $204000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for BCYC at $204000.0 in Q3 2025, $236000.0 in Q2 2025, and $309000.0 in Q1 2025.